Sire Bioscience Inc. (SIRE) (CSE:SIRE, FRA:BR1B,OTCX:BLLXF), a Health Canada hemp license holder with a goal of becoming a vertically integrated CPG leader in the CBD marketplace, is pleased to announce the Company has commenced discussions, as well as entered into a non-binding Cannabidiol (“CBD”) Commercialization and Consulting Letter of Intent (“LOI”), dated September 24, 2019, with Fusion Nutrition Inc. (“FUSION”),  a nationally branded supplement manufacturer.

The 20 year old Canadian-based, leading supplement company has national distribution and currently hosts up to 9 brands, including PURPLE-K, the king of creatine. Fusion Nutrition has some of the fastest-growing supplements in Canada and numerous category leaders sold in Canada’s top five sports nutrition retailers. To add more depth to their lineup, Fusion is also currently ramping up the release of its protein powder called PROZILLA. You can learn more about Fusion Nutrition at fusionmuscle.com.


sire

Ryan Herniman, Fusion President, comments, “Within the sports nutrition space a more obvious synergy has never presented itself. With our combined experience in the world of CPG’s we’ll not only be able to develop world-class offerings but we’ll be able to help a lot of people and that motivates us tremendously. It’s an exciting new time in sports nutrition and we’re thrilled to be working with Sire on this initiative.”

The sports nutrition market is vast – covering a wide range of categories such as protein powders, protein bars, branched-chain amino acids (BCAAs), pre-workout blends, nitric oxide boosters, and creatine supplements. Largely driven by the Millennial demographic, the market shows no signs of slowing down. According to Allied Market Research, the global sports nutrition market is expected to reach $44 billion by 2021.

Meanwhile, cannabis industry analyst, Brightfield Group, advises the hemp-CBD market alone could hit $22 billion by 2022. Brightfield Group also comments that CBD trials have been found to be particularly effective at treating conditions of pain, sleep disturbance, spasticity, and seizures, as well as decreasing one’s dependency on other drugs such as opioids.

Jeff Zanini, Sire CEO, comments, “The union of these two massive industries will create a business-related sonic boom. Sports nutrition combined with CBD is a winning formula. It’s also aligned with everything that Sire is all about – such as having an early-mover advantage to win the CPG race, staying on the fastest track to revenue and profits, and elevating the consciousness of humanity, all while sustainably increasing shareholder value.  This is a pure winner and we couldn’t be more excited.”

The non-binding LOI contemplates the branded and private label creation and supply of Sire’s House of Brands portfolio of CBD-infused CPG products.

Terms of the LOI include but are not limited to:

  • Scientific study and analysis of the CBD/sports nutrition industry to ensure best-in-class deliverable methods.
  • Regulatory analysis to ensure compliance with regulatory bodies in Canada, supporting fastest “go-to-market” strategy.
  • Exclusivity of arrangement between SIRE and FUSION.
  • Exchange of Branding, Licensing and Intellectual Property.

There is no guarantee the transaction proposed will be completed.  Sire will provide further disclosure by way of press release and updates as such additional information becomes available.

About Sire Bioscience
Sire’s principal business activity is to engage in the investment, production of and sale of hemp for CBD extraction. Sire has its wholly-owned, state-of-the-art facility in Leamington, Ontario – a preeminent locale for hemp cultivation in Canada. The land parcel includes 50 acres of prime horticultural land, with a 160,000 sq. ft facility of combined greenhouse and indoor space. Our goal is to become a vertically integrated CPG life science company with our “House of Brands” offering.  Sire is headquartered in Toronto, Ontario and is backed by a group of successful entrepreneurs who have extensive experience in the areas of manufacturing, logistics, and renewable energy.

FOR INFORMATION, CONTACT:

Sire Bioscience Inc.
Jeff Zanini
CEO
E: jeff@sirebioscience.com
T: 416-262-0871

The CSE and Information Service Provider have not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

Forward-looking Information Cautionary Statement
No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release. Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.

Click here to connect with Sire Bioscience (CSE:SIRE) for an Investor Presentation.

Source

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less